Literature DB >> 9061690

The effects of the growth factor-antagonist, trapidil, on remyelination in the CNS.

J S McKay1, W F Blakemore, R J Franklin.   

Abstract

In this study we describe the effects of trapidil, a putative platelet-derived growth factor-antagonist, on spontaneously occurring remyelination in rat spinal cord. Demyelination was created in the dorsal funiculus of 6- and 11-week-old female rats by the direct injection of 1.0 microliter of 1% lysolecithin. The animals received daily intra-peritoneal injections of either trapidil or saline for 21 days, commencing on the day of lesion induction. The 11-week-old rats receiving trapidil (60 mg/kg) showed a significant decrease in the extent of oligodendrocyte remyelination. Moreover, those axons that were remyelinated by oligodendrocytes tended to have thinner myelin sheaths than axons remyelinated by oligodendrocytes in the control group. In the 6-week-old group, the dose of trapidil which inhibited oligodendrocyte remyelination in the 11-week-old animals had a minimal effect on the extent of oligodendrocyte remyelination and no effect on the quality of myelin sheath formation. A higher dose of trapidil (80 mg/kg) was required before significant impairment of oligodendrocyte remyelination was achieved in the younger age group, implying an age-dependent effect of growth factor-inhibition of CNS remyelination. These results indicate an important role for growth factors, and in particular PDGF, in the orchestration of oligodendrocyte remyelination in the rodent CNS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061690

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  6 in total

Review 1.  Stem cell-based therapies for spinal cord injury.

Authors:  Rishi S Nandoe Tewarie; Andres Hurtado; Ronald H Bartels; Andre Grotenhuis; Martin Oudega
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

Review 2.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

Review 3.  Macrophages in CNS remyelination: friend or foe?

Authors:  L T Diemel; C A Copelman; M L Cuzner
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 4.  Therapeutic strategies in multiple sclerosis. II. Long-term repair.

Authors:  N Scolding
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

5.  Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis.

Authors:  Carlijn R Hooijmans; Martin Hlavica; Florian A F Schuler; Nicolas Good; Andrin Good; Lisa Baumgartner; Gianluca Galeno; Marc P Schneider; Tarzis Jung; Rob de Vries; Benjamin V Ineichen
Journal:  Sci Rep       Date:  2019-01-29       Impact factor: 4.379

Review 6.  What roles do growth factors play in CNS remyelination?

Authors:  R J Franklin; G L Hinks; R H Woodruff; M T O'Leary
Journal:  Prog Brain Res       Date:  2001       Impact factor: 2.453

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.